Minerva Neurosciences, Inc. carries a market capitalization of 33.22M, placing it among publicly traded companies globally. Its enterprise value stands at 27.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 33.22M |
| Enterprise Value | 27.70M |
Minerva Neurosciences, Inc. currently has 43.84M shares outstanding.
| Shares Outstanding | 43.84M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Minerva Neurosciences, Inc. trades at a trailing price-to-earnings ratio of 0.87.
| PE Ratio | 0.87 |
| PS Ratio | N/A |
| PB Ratio | -0.13 |
| P/TBV Ratio | -0.39 |
| P/FCF Ratio | -7.11 |
| P/OCF Ratio | -7.11 |
Minerva Neurosciences, Inc. maintains a current ratio of 17.65, meaning it holds 17.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 17.65 |
| Quick Ratio | 17.42 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -654.56 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Minerva Neurosciences, Inc.'s stock has gained approximately 169.88636% over the past 52 weeks. The 50-day moving average sits at 5.83, while the 200-day moving average is 4.54.
| Beta (5Y) | N/A |
| 52-Week Price Change | 169.88636% |
| 50-Day Moving Average | 5.83 |
| 200-Day Moving Average | 4.54 |
| Average Volume (20 Days) | N/A |
EBITDA reached -27.87M, while operating income came in at -27.87M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -27.87M |
| Pretax Income | -415.07M |
| Net Income | -415.07M |
| EBITDA | -27.87M |
| EBIT | -27.87M |
| Earnings Per Share (EPS) | -23.67 |
Total book value stands at -814.20M, with working capital of 74.62M providing operational flexibility.
| Cash & Cash Equivalents | 78.06M |
| Total Debt | N/A |
| Net Debt | -32.66M |
| Equity (Book Value) | -814.20M |
| Book Value Per Share | -46.42 |
| Working Capital | 74.62M |
Minerva Neurosciences, Inc. produced -14.87M in operating cash flow over the past twelve months.
| Operating Cash Flow | -14.87M |
| Capital Expenditures | N/A |
| Free Cash Flow | -14.87M |
| FCF Per Share | -0.85 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -71.42 |
| FCF Yield | -14.06 |
Minerva Neurosciences, Inc.'s most recent stock split took place on June 21, 2022 with a 8:1 split ratio.
| Last Split Date | 6/21/2022 |
| Split Ratio | 8:1 |
Minerva Neurosciences, Inc. posts an Altman Z-Score of -14.25, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -14.25 |